Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Tim Kutzkey
AddedMar 31, 2024
UpdatedMay 31, 2026
Tim Kutzkey

Tim Kutzkey

Board Member, Surrozen

Crunchbase

Tim Kutzkey's Career

Surrozen
Surrozen

South San Francisco, CA, US

Board Member· Board
Nurix
Nurix

San Francisco, CA, US

Board Member· Board
Cyterix Pharmaceuticals
Cyterix Pharmaceuticals

San Francisco, CA, US

Board Member· Board
Plexium
Plexium

San Diego, CA, US

Board Member· Board
Peloton Therapeutics
Peloton Therapeutics

Dallas, TX, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Tim Kutzkey's Career

Surrozen
Surrozen
Public$253M792016South San Francisco, CA, US
Board Member· Board

Leadership at Surrozen

Calvin KuoCalvin KuoCo-Founder
Shao-Lee LinShao-Lee LinBoard Member
Roel NusseRoel NusseCo-Founder
Craig ParkerCraig ParkerCEO
Claudia JandaClaudia JandaCo-Founder
Mary Haak-FrendschoMary Haak-FrendschoBoard Member
Nurix
Nurix
Public$370.9M2972012San Francisco, CA, US
Board Member· Board

Leadership at Nurix

Michael RapeMichael RapeBoard Member
David GoeddelDavid GoeddelBoard Member
Jeffrey TongJeffrey TongBoard Member
Arthur T. SandsArthur T. SandsBoard Member
Perry KarsenPerry KarsenBoard Member
Julia P. GregoryJulia P. GregoryBoard Member

Similar to Nurix

ArvinasArvinasNew Haven, CT, USTherapeuticsest. 2013ArvinasNew Haven, CT, US · est. 2013

US-based Arvinas, Inc. develops protein degradation therapeutics for cancer and other diseases globally.

Public · $461.6M415
Innovo TherapeuticsInnovo TherapeuticsSan Diego, CA, USAnti-Cancer Drugsest. 2021Innovo TherapeuticsSan Diego, CA, US · est. 2021

San Diego-based Innovo Therapeutics develops anti-cancer drugs targeting protein breakdown.

Seed · $200M11
NeomorphNeomorphSan Diego, CA, USDrug Discoveryest. 2020NeomorphSan Diego, CA, US · est. 2020

Neomorph, a San Diego-based biotech firm, innovates new medicines to solve critical health issues.

Series A · $109M62
Cyterix Pharmaceuticals
Cyterix Pharmaceuticals
Acquired$16.5M02010San Francisco, CA, US
Board Member· Board

Leadership at Cyterix Pharmaceuticals

Steven A EverettSteven A EverettBoard Member
Dr Lutz B GiebelDr Lutz B GiebelBoard Member

Similar to Cyterix Pharmaceuticals

CytomX TherapeuticsCytomX TherapeuticsSouth San Francisco, CA, USCancer Treatmentsest. 2010CytomX TherapeuticsSouth San Francisco, CA, US · est. 2010

CytomX Therapeutics: A US-based oncology-focused biopharmaceutical firm specializing in probody cancer treatments.

Public · $345.4M174
OncolixOncolixHouston, TX, USCancer Treatmentest. 2007OncolixHouston, TX, US · est. 2007

Oncolix: A clinical-stage biotech firm innovating therapeutic proteins for cancer treatment.

Series A · $8.5M30
Altiris TherapeuticsAltiris TherapeuticsAtlanta, GA, USCancer Drugs, HIV Drugsest. 2005Altiris TherapeuticsAtlanta, GA, US · est. 2005

Innovative cancer and HIV drug developer. Founded in 2005.

Public · $46.3M750
Plexium
Plexium
Series B$165M942018San Diego, CA, US
Board Member· Board

Leadership at Plexium

Mike GreyMike GreyBoard Member
Andrew MacConnellAndrew MacConnellCo-Founder
Brian WongBrian WongBoard Member
Kiersten SteadKiersten SteadBoard Member
Rob HopfnerRob HopfnerBoard Member
Joe RokickiJoe RokickiCo-Founder

Similar to Plexium

NurixNurixSan Francisco, CA, USDrugsest. 2012NurixSan Francisco, CA, US · est. 2012

San Francisco-based Nurix Therapeutics develops novel drugs, harnessing natural processes to treat cancer.

Public · $370.9M297
NeomorphNeomorphSan Diego, CA, USDrug Discoveryest. 2020NeomorphSan Diego, CA, US · est. 2020

Neomorph, a San Diego-based biotech firm, innovates new medicines to solve critical health issues.

Series A · $109M62
Differentiated TherapeuticsDifferentiated TherapeuticsBoston, MA, USTPD Therapiesest. 2021Differentiated TherapeuticsBoston, MA, US · est. 2021

Distinct Therapeutics designs and develops innovative TPD therapies for patients with unmet medical needs.

Seed · $5M6
Peloton Therapeutics
Peloton Therapeutics

Dallas, TX, US

Board Member· Board

Tim Kutzkey's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Tim Kutzkey

Cory R NicholasCory R NicholasFounder · Neurona TherapeuticsShadrach Benny RetnamonyShadrach Benny RetnamonyCo-Founder · NeuronKeith SullivanKeith SullivanCEO · NeuroneticsPaul L. BernsPaul L. BernsBoard Member · Unity BiotechnologyScott KerseyScott KerseyCo-Founder · NeuronKevin DerrKevin DerrCo-Founder · NeuronSphere